<DOC>
	<DOCNO>NCT00876252</DOCNO>
	<brief_summary>Randomized , placebo-controlled , partially blind phase 2 pilot study . Multicenter study ( approximately 50 center ) approximately 9 country . Proposed start date December 2008 . The study duration per patient estimate 90 day . Overall study duration estimate 12-18 month .</brief_summary>
	<brief_title>Study Assessing Immunogenicity Safety IC43 In Intensive Care Patients</brief_title>
	<detailed_description>This randomize , placebo‐controlled , multi‐center , partially blind [ i.e. , 100 mcg 200 mcg IC43 Al ( OH ) 3 , , respectively ] placebo , unblinded non‐adjuvanted IC43 [ i.e. , 100 mcg w/o Al ( OH ) 3 ] phase 2 pilot study . The study population consist male female ICU patient need mechanical ventilation 48 hour , age 18 80 year .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Male female patient age 18 80 year Patients admit ICU need mechanical ventilation 48 hour visit 0 At high risk acquire infection P. aeruginosa visit 0 . Patients , determine investigator , high probability survival least 48 hour . In female , either childbearing potential terminate surgery 1 year post menopausal , negative pregnancy test willingness practice reliable method contraception Written inform consent waiver accord national regulation Known use investigational nonregistered drug within 30 day prior IC43 vaccination Visit 0 Low severity illness define acute physiology score &lt; 8 visit 0 Patients &lt; 6 month post organ transplantation Severe thrombocytopenia coagulopathy opinion investigator make patient unsuitable intramuscular injection Pregnancy , lactation Persons commit involuntarily institution , e.g . mental health facility prison , participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>